Publications

2018

Efficacy of Combination FDL169/FDL176 is Greater than Tezacaftor/Ivacaftor

Properties of F508del-CFTR Potentiator FDL176

Properties of F508del-CFTR Second Site Corrector FD2052160

2017

Distinguishing Properties of CFTR Potentiator FDL176

Preclinical in vitro Evaluation: Combination FD169/FDL176 is Superior to Tezacaftor/Ivacaftor

2016

Effect of Four Sets of Distinct Modulators on Non-F508del Mutations that Cause Cystic Fibrosis

Effect of Novel F508del-CFTR Modulator Combination FDL169 and FDL176 on Expression and Functional Activ

A New Combination of CFTR Modulators Corrects Processing and Reduces Chronic Inhibition of F508del-CFTR

Properties of a Novel F508del-CFTR Corrector FDL169

2015

Lung Partitioning of deltaF508-CFTR Corrector

Fixing ΔF508-CFTR – Bringing New Correctors into the Fold

2014

The Potentiator FD2033129 Does Not Chronically Reduce deltaF508 CFTR Function in Contrast to VX-770

New Pathways to CFTR Correction

2013

Discovery and Development of Novel deltaF508-CFTR Correctors

Combination Screen for CFTR Modulators at FDL

High Throughput Combination Screening for deltaF508-CFTR Modulation with Small Molecules

The Path to 30% and Beyond: Discovery and Development of Second Generation CFTR Modulators

Current Team Members

Andrew Kolodziej
Eric Lu
Feng Li
Iris Kwok
Jenna Tagliaferri
Jingwen Chai
John Ferkany
John Flatley
Justin Chin
Mario Gamboa
Mary Hoffee
Mauri Krouse
Mike Zawistoski
Priyanka Bhatt
Richard Fitzpatrick
Richard Oliver
Timothy O’Toole
Violaine Bailey

Past Contributors

FDL would like to acknowledge the following individuals for their important contributions to our research efforts:

Have an Idea?

We’d love to hear it!